Common genetic variants associated with melanoma risk or naevus count in patients with wildtype MC1R melanoma.


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
11 2022
Historique:
revised: 07 06 2022
received: 07 03 2022
accepted: 11 06 2022
pubmed: 15 6 2022
medline: 5 11 2022
entrez: 14 6 2022
Statut: ppublish

Résumé

Hypomorphic MC1R variants are the most prevalent genetic determinants of melanoma risk in the white population. However, the genetic background of patients with wildtype (WT) MC1R melanoma is poorly studied. To analyse the role of candidate common genetic variants on the melanoma risk and naevus count in Spanish patients with WT MC1R melanoma. We examined 753 individuals with WT MC1R from Spain (497 patients and 256 controls). We used OpenArray reverse-transcriptase polymerase chain reaction to genotype a panel of 221 common genetic variants involved in melanoma, naevogenesis, hormonal pathways and proinflammatory pathways. Genetic models were tested using multivariate logistic regression models. Nonparametric multifactor dimensionality reduction (MDR) was used to detect gene-gene interactions within each biological subgroup of variants. We found that variant rs12913832 in the HERC2 gene, which is associated with blue eye colour, increased melanoma risk in individuals with WT MC1R [odds ratio (OR) 1·97, 95% confidence interval (CI) 1·48-2·63; adjusted P < 0·001; corrected P < 0·001]. We also observed a trend between the rs3798577 variant in the oestrogen receptor alpha gene (ESR1) and a lower naevus count, which was restricted to female patients with WT MC1R (OR 0·51, 95% CI 0·33-0·79; adjusted P = 0·002; corrected P = 0·11). This sex-dependent association was statistically significant in a larger cohort of patients with melanoma regardless of their MC1R status (n = 1497; OR 0·71, 95% CI 0·57-0·88; adjusted P = 0·002), reinforcing the hypothesis of an association between hormonal pathways and susceptibility to melanocytic proliferation. Last, the MDR analysis revealed four genetic combinations associated with melanoma risk or naevus count in patients with WT MC1R. Our data suggest that epistatic interaction among common variants related to melanocyte biology or proinflammatory pathways might influence melanocytic proliferation in individuals with WT MC1R. What is already known about this topic? Genetic variants in the MC1R gene are the most prevalent melanoma genetic risk factor in the white population. Still, 20-40% of cases of melanoma occur in individuals with wildtype MC1R. Multiple genetic variants have a pleiotropic effect in melanoma and naevogenesis. Additional variants in unexplored pathways might also have a role in melanocytic proliferation in these patients. Epidemiological evidence suggests an association of melanocytic proliferation with hormonal pathways and proinflammatory pathways. What does this study add? Variant rs12913832 in the HERC2 gene, which is associated with blue eye colour, increases the melanoma risk in individuals with wildtype MC1R. Variant rs3798577 in the oestrogen receptor gene is associated with naevus count regardless of the MC1R status in female patients with melanoma. We report epistatic interactions among common genetic variants with a role in modulating the risk of melanoma or the number of naevi in individuals with wildtype MC1R. What is the translational message? We report a potential role of hormonal signalling pathways in melanocytic proliferation, providing a basis for better understanding of sex-based differences observed at the epidemiological level. We show that gene-gene interactions among common genetic variants might be responsible for an increased risk for melanoma development in individuals with a low-risk phenotype, such as darkly pigmented hair and skin.

Sections du résumé

BACKGROUND
Hypomorphic MC1R variants are the most prevalent genetic determinants of melanoma risk in the white population. However, the genetic background of patients with wildtype (WT) MC1R melanoma is poorly studied.
OBJECTIVES
To analyse the role of candidate common genetic variants on the melanoma risk and naevus count in Spanish patients with WT MC1R melanoma.
METHODS
We examined 753 individuals with WT MC1R from Spain (497 patients and 256 controls). We used OpenArray reverse-transcriptase polymerase chain reaction to genotype a panel of 221 common genetic variants involved in melanoma, naevogenesis, hormonal pathways and proinflammatory pathways. Genetic models were tested using multivariate logistic regression models. Nonparametric multifactor dimensionality reduction (MDR) was used to detect gene-gene interactions within each biological subgroup of variants.
RESULTS
We found that variant rs12913832 in the HERC2 gene, which is associated with blue eye colour, increased melanoma risk in individuals with WT MC1R [odds ratio (OR) 1·97, 95% confidence interval (CI) 1·48-2·63; adjusted P < 0·001; corrected P < 0·001]. We also observed a trend between the rs3798577 variant in the oestrogen receptor alpha gene (ESR1) and a lower naevus count, which was restricted to female patients with WT MC1R (OR 0·51, 95% CI 0·33-0·79; adjusted P = 0·002; corrected P = 0·11). This sex-dependent association was statistically significant in a larger cohort of patients with melanoma regardless of their MC1R status (n = 1497; OR 0·71, 95% CI 0·57-0·88; adjusted P = 0·002), reinforcing the hypothesis of an association between hormonal pathways and susceptibility to melanocytic proliferation. Last, the MDR analysis revealed four genetic combinations associated with melanoma risk or naevus count in patients with WT MC1R.
CONCLUSIONS
Our data suggest that epistatic interaction among common variants related to melanocyte biology or proinflammatory pathways might influence melanocytic proliferation in individuals with WT MC1R. What is already known about this topic? Genetic variants in the MC1R gene are the most prevalent melanoma genetic risk factor in the white population. Still, 20-40% of cases of melanoma occur in individuals with wildtype MC1R. Multiple genetic variants have a pleiotropic effect in melanoma and naevogenesis. Additional variants in unexplored pathways might also have a role in melanocytic proliferation in these patients. Epidemiological evidence suggests an association of melanocytic proliferation with hormonal pathways and proinflammatory pathways. What does this study add? Variant rs12913832 in the HERC2 gene, which is associated with blue eye colour, increases the melanoma risk in individuals with wildtype MC1R. Variant rs3798577 in the oestrogen receptor gene is associated with naevus count regardless of the MC1R status in female patients with melanoma. We report epistatic interactions among common genetic variants with a role in modulating the risk of melanoma or the number of naevi in individuals with wildtype MC1R. What is the translational message? We report a potential role of hormonal signalling pathways in melanocytic proliferation, providing a basis for better understanding of sex-based differences observed at the epidemiological level. We show that gene-gene interactions among common genetic variants might be responsible for an increased risk for melanoma development in individuals with a low-risk phenotype, such as darkly pigmented hair and skin.

Identifiants

pubmed: 35701387
doi: 10.1111/bjd.21707
pmc: PMC9804579
doi:

Substances chimiques

Receptor, Melanocortin, Type 1 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

753-764

Informations de copyright

© 2022 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.

Références

Cancer Treat Res. 2016;167:17-49
pubmed: 26601858
Nat Immunol. 2016 Jul 19;17(8):906-13
pubmed: 27434011
Br J Dermatol. 2015 Apr;172(4):1081-9
pubmed: 25307738
J Eur Acad Dermatol Venereol. 2021 Feb;35(2):e135-e138
pubmed: 32780924
Int J Mol Sci. 2020 Mar 05;21(5):
pubmed: 32150843
Br J Dermatol. 2020 Jan;182(1):138-146
pubmed: 31016712
J Invest Dermatol. 2001 Aug;117(2):348-52
pubmed: 11511314
Photodermatol Photoimmunol Photomed. 2018 Nov;34(6):415-422
pubmed: 29974532
Inflamm Bowel Dis. 2010 Jul;16(7):1108-17
pubmed: 20024904
J Natl Cancer Inst. 2000 Mar 15;92(6):457-63
pubmed: 10716963
Eur J Cancer. 2005 Jan;41(1):28-44
pubmed: 15617989
Int J Cancer. 2015 Mar 15;136(6):1351-60
pubmed: 25077817
Int J Cancer. 2008 Jun 15;122(12):2753-60
pubmed: 18366057
Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):293-300
pubmed: 27759434
PLoS Med. 2014 Jun 10;11(6):e1001660
pubmed: 24915306
Cancer Manag Res. 2018 May 14;10:1143-1154
pubmed: 29795986
Cancer. 2019 Nov 1;125(21):3714-3728
pubmed: 31318440
Clin Gastroenterol Hepatol. 2014 Feb;12(2):210-8
pubmed: 23644389
Forensic Sci Int Genet. 2014 Jul;11:64-72
pubmed: 24681889
Carcinogenesis. 2020 Jun 17;41(4):452-457
pubmed: 31630191
BMC Cancer. 2013 Jul 02;13:325
pubmed: 23816148
Fam Cancer. 2010 Dec;9(4):625-33
pubmed: 20574843
Pigment Cell Melanoma Res. 2018 Jan;31(1):39-50
pubmed: 28950052
Dermatology. 2009;218(3):203-14
pubmed: 19060476
BMC Cancer. 2020 Nov 9;20(1):1069
pubmed: 33167923
Br J Dermatol. 2006 May;154(5):880-4
pubmed: 16634890
Hum Hered. 2009;67(3):183-92
pubmed: 19077437
Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):2043-54
pubmed: 20647408
J Invest Dermatol. 2006 Aug;126(8):1842-9
pubmed: 16601669
J Eur Acad Dermatol Venereol. 2013 Feb;27(2):e179-85
pubmed: 22621339
Nat Genet. 2008 Aug;40(8):955-62
pubmed: 18587394
Am J Hum Genet. 2008 Feb;82(2):424-31
pubmed: 18252222
Nat Commun. 2018 Nov 14;9(1):4774
pubmed: 30429480
Cancer Treat Rev. 2018 Sep;69:21-28
pubmed: 29864718
Nat Rev Genet. 2004 Aug;5(8):618-25
pubmed: 15266344
PLoS Med. 2014 Jun 10;11(6):e1001659
pubmed: 24915186
Ann Transl Med. 2015 Sep;3(15):210
pubmed: 26488006
J Dermatol Sci. 2016 Nov;84(2):137-143
pubmed: 27461758
Methods Mol Biol. 2013;1019:465-77
pubmed: 23756906
Methods Mol Biol. 2015;1253:301-14
pubmed: 25403539
Neoplasma. 2010;57(4):306-15
pubmed: 20429621
J Invest Dermatol. 2014 Feb;134(2):481-487
pubmed: 23892592
Eur J Cancer. 2005 Sep;41(14):2040-59
pubmed: 16125929
J Theor Biol. 2006 Jul 21;241(2):252-61
pubmed: 16457852
Crit Rev Oncol Hematol. 2020 Aug;152:102989
pubmed: 32485529
Hum Genet. 2008 Mar;123(2):177-87
pubmed: 18172690
Hum Genomics. 2006 Mar;2(5):318-28
pubmed: 16595076
J Hum Genet. 2011 Jan;56(1):5-7
pubmed: 20944644
Hum Mol Genet. 2011 Dec 15;20(24):5012-23
pubmed: 21926416
Gynecol Oncol. 2019 Jul;154(1):199-206
pubmed: 30987772
Front Immunol. 2020 Oct 09;11:588682
pubmed: 33163004
Nature. 2007 Jun 7;447(7145):661-78
pubmed: 17554300
Nat Genet. 2020 May;52(5):494-504
pubmed: 32341527
Nat Genet. 2009 Aug;41(8):915-9
pubmed: 19578365
Nat Genet. 2007 Jul;39(7):830-2
pubmed: 17554261
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Br J Dermatol. 2011 Jun;164(6):1262-70
pubmed: 21574971
Photochem Photobiol. 2015 Jan-Feb;91(1):188-200
pubmed: 25155575
Blood. 2005 Jan 1;105(1):13-21
pubmed: 15353480
Nat Genet. 2010 Dec;42(12):1118-25
pubmed: 21102463
Melanoma Res. 2020 Oct;30(5):511-514
pubmed: 32732695
Br J Dermatol. 2016 Feb;174(2):356-63
pubmed: 26871925
Hum Hered. 2003;56(1-3):73-82
pubmed: 14614241
Pathol Oncol Res. 2010 Dec;16(4):485-96
pubmed: 20383761
Nat Rev Genet. 2018 Sep;19(9):581-590
pubmed: 29789686
PLoS Genet. 2007 Apr 20;3(4):e58
pubmed: 17447842
Genet Epigenet. 2016 Feb 24;8:1-6
pubmed: 26949342
J Natl Cancer Inst. 2005 Jul 6;97(13):998-1007
pubmed: 15998953
Am J Hum Genet. 2016 Feb 4;98(2):243-55
pubmed: 26833331
Genet Med. 2016 Jul;18(7):727-36
pubmed: 26681309
Pigment Cell Melanoma Res. 2020 Sep;33(5):685-694
pubmed: 32323445
JAMA Dermatol. 2020 May 1;156(5):553-560
pubmed: 32211827
Gastroenterology. 2012 Aug;143(2):390-399.e1
pubmed: 22584081
Acta Derm Venereol. 2017 Mar 10;97(3):321-324
pubmed: 27868146

Auteurs

Neus Calbet-Llopart (N)

Dermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.

Marc Combalia (M)

Dermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

Anil Kiroglu (A)

Dermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

Miriam Potrony (M)

Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.
Biochemistry and Molecular Genetics Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

Gemma Tell-Martí (G)

Dermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.

Andrea Combalia (A)

Dermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

Albert Brugues (A)

Dermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

Sebastian Podlipnik (S)

Dermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

Cristina Carrera (C)

Dermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.

Susana Puig (S)

Dermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.

Josep Malvehy (J)

Dermatology Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.

Joan Anton Puig-Butillé (JA)

Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Barcelona, Spain.
Molecular Biology CORE, Biochemistry and Molecular Genetics Department, Melanoma Group, Hospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH